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Abstract
Dyslipidemia is a major risk factor for cardiovascular disease (CVD). The relationship
between low-density lipoprotein concentration and cardiovascular (CV) risk has been
well  established  in  numerous  epidemiological  studies.  The  benefit  of  cholesterol-
lowering agents has been demonstrated in patients with known CVD. On the other
hand, in patients without known CVD the decision to start therapy depends on their
10-year risk prediction of CV events. 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (“statins”), a mainstay of cholesterol-lowering therapy, have
been shown to reduce both CV events and all-cause mortality. Other lipid-lowering
measures (both pharmacological and nonpharmacological) have also been demonstrat-
ed in clinical trials to reduce CV outcomes. In this chapter, we review contemporary
therapies used to treat  dyslipidemia and discuss future directions including novel
agents on the horizon.
Keywords: cholesterol treatment, cardiovascular disease, dyslipidemia, cardiovascu-
lar risk stratification, hypercholesterolemia
1. Introduction
Atherosclerotic cardiovascular disease (CVD) affects more than 15 million Americans and is
considered the leading cause of death in the United States (US) in both men and women (REF).
Dyslipidemia is a major risk factor for atherosclerotic CVD [1]. We review current standard
treatment of abnormal cholesterol levels and discuss future directions. Lipid-altering therapies
favorably impact the lipid profile by lowering total cholesterol, low-density lipoprotein (LDL),
and triglycerides (TGs), while beneficially increasing high-density lipoprotein (HDL; see Table
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1) [2–4]. In addition, lipid-altering therapies cause a desirable shift toward less atherogenic
cholesterol  subparticles  [5].  The  benefit  of  lipid  therapy  has  been  borne  out  in  studies
evaluating their effects on coronary atherosclerosis regression (by angiography) and incidence
of major adverse cardiovascular events (MACEs) [6–10]. The lipoprotein transport system
mediates the movement of cholesterol and TG in plasma, in addition to numerous other
important  physiologic  functions.  These  include  transport  of  dietary  fat  absorbed  in  the
intestines to the liver, transport of modified cholesterol to peripheral tissues for cell membrane
and steroid hormone synthesis, and transport of free fatty acids that may be used for fuel [11].
Lipoproteins are typically classified by their size and density. The main lipoprotein carriers of
cholesterol to peripheral tissues are LDL particles. They are internalized by LDL receptors,
where they are then hydrolyzed. This is an important pathway in controlling plasma choles-
terol levels, as evidenced in those with loss-of-function mutations of LDL receptors leading to
an inherited hyperlipidemia [12]. Importantly, LDL particles vary in size. Those with fewer
cholesteryl esters and more TGs are smaller, denser, and thus more atherogenic [11].
Drug class LDL (%) HDL (%) TG (%)
Bile acid sequestrants ↓ 15–30 ↑ 3–5 No change
Cholesterol absorption inhibitors (Ezetimibe) ↓ 17–22 ↑ 2–5 ↓ 4–11
Fibrates ↓ 5–20 ↑ 10–20 ↓ 20–50
Nicotinic acid (niacin) ↓ 5–25 ↑ 15–35 ↓ 20–50
PCSK9 inhibitors ↓ 61–62 ↑ 5–7 ↓ 13–17
HMG-CoA reductase inhibitors (Statins) ↓ 18–55 ↑ 5–15 ↓ 7–30
Abbreviations: LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein; TC, total cholesterol; TG,
triglycerides.
Table 1. Potencies of various lipid lowering agents.
Increased concentrations of LDL have been shown in epidemiological studies to be associated
with an increased risk of MACE. This was demonstrated in The Lipid Research Clinics
Prevalence Study, where after 10 years of follow-up in patients with known coronary heart
disease (CHD), a higher death rate was evident in those with higher levels of plasma total
cholesterol and LDL [13]. In addition, those with inherited hyperlipidemia have early athero-
thrombosis [14]. Reducing LDL cholesterol is strongly linked to reductions in MACE, espe-
cially when using statins [10]. One-third of all middle-aged or older adults in the general
population of the US and United Kingdom (UK) have an indication for statin therapy [15].
Notably decreased LDL and raising HDL levels have been associated with regression of
atherosclerosis as evident in the Regression Growth Evaluation Statin Study (REGRESS) trial
and several other trials [6–9].
Until recently, it was strongly recommended to treat to specific LDL targets [16]. These targets
were based on post hoc analyses demonstrating greater reductions in MACE with LDL levels
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below certain levels. However, subsequent head-to-head statin trials compared different
agents at different doses. These studies did not investigate the effects of different LDL target
levels [17]. For such reasons, the most recent US guidelines advocate for using high-intensity
statins for patients at high risk of cardiovascular events. By contrast, guidelines in Europe and
Canada have maintained their recommendation on using LDL targets [18].
Statins are well known for pleotropic effects independent of cholesterol lowering, mainly anti-
inflammatory properties [19]. In many statin trials, subjects with the largest reduction in high-
sensitivity C-reactive protein (hsCRP) have decreased primary end points [20, 21]. In two statin
trials, lower hsCRP and LDL levels were associated with a decrease in atheroma progression
as assessed by serial intravascular ultrasound observation [22, 23]. Moreover, in the Justifica-
tion for the Use of Statins in Prevention (JUPITER) trial, a decrease in MACE and all-cause
mortality was seen in asymptomatic subjects with baseline elevated hsCRP levels and already
low LDL level, which contemporary risk calculators would exclude from therapy. Notably,
elevated LDL cholesterol is associated with MACE without the need for overt evidence of
inflammation [24] .
1.1. Cardiovascular risk stratification: Who to treat?
In patients with known CVD, treatment with statins has been shown to reduce CV events and
all-cause mortality, while other lipid-lowering agents have also been shown to reduce the
incidence of CV events in patients not on statins [25–33]. However, in patients without known
CVD, cholesterol-lowering agents have only been shown to be beneficial in those at a high risk
of CV events. The absolute benefit of treatment is proportional to the underlying absolute CV
risk. Therefore, it is important to target patients at a high risk of CV events rather than a specific
LDL.
Various CV risk calculators have been used to identify patients at high risk. These calculators
are modeled to a particular population; therefore, the choice of which risk calculator to use is
important. Below, we will discuss the benefits and pitfalls of using risk calculators to guide
decision to treat. The Framingham Risk score is a risk calculator based on a population from
the northeastern US (https://www.framinghamheartstudy.org/risk-functions/cardiovascular-
disease/10-year-risk.php#). The most current version includes major CV outcomes, stroke, and
heart failure. Notably, statins have shown to reduce the incidence of major CV outcomes and
stroke, but not heart failure [34]. The American Heart Association/American College of
Cardiology (AHA/ACC) Pooled Cohort Equations Cardiovascular risk calculator (ASCVD) is
based on a population of non-Hispanic whites and African Americans in the US (http://
tools.acc.org/ASCVD-Risk-Estimator/). Compared to the Framingham risk calculator, it
predicts major CV outcomes that are reduced by statins. Limitations of the ASCVD include its
dichotomization of diabetes mellitus without considering its duration or type. It also does not
take into account family history of premature CV disease, thus underestimating CV risk in
those with significant family history of CV events [35].
The Joint British Societies (JBS-3) guidelines calculator is based on a population from the UK
(http://www.jbs3risk.com/JBS3Risk.swf). In those with a low 10-year risk of CV events, the
JBS-3 recommends using the QRISK® lifetime CV risk calculator [36]. Both the ASCVD and
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JBS-3 predict both 10-year risk and lifetime risk of CV events. Without the data with long-term
effects of statins, there is a limitation to use lifetime risk prediction for using cholesterol-
lowering agents. Therefore, the use of the 10-year risk predictions has been recommended
when making such decisions. In patient with diabetes, the UK Prospective Diabetes Study
calculator incorporates factors important to those with diabetics that are not found in the
ASCVD calculator such as diabetes duration and type [37].
Another factor used when making the decision to treat on a population-based approach is
cost-effectiveness. The 2013 AHA/ACC guidelines have recommended the use of a 10-year risk
of CV events threshold of 7.5% when deciding to use cholesterol-lowering agents. This was
found to be more cost-effective when compared with ≥10% threshold [38].
In older patients, over age 65, the decision to treat is also influenced by the presence of other
comorbidities not taken into account in the calculators above. For example, a patient with a
concurrent illness with high mortality, such as metastatic pancreatic cancer, is unlikely to
benefit from a cholesterol-lowering agent. Thus, clinical trials of cholesterol-lowering agents
have typically excluded older patients. However, a healthy elderly patient may potentially
benefit from these therapies, and in fact the absolute number to treat is much lower in a healthy
elderly population, given the dramatic increase in absolute risk of CV disease in this cohort
[39]. A barrier to using cholesterol-lowering agents in the elderly has been the notion that it
takes years to see the benefit of cholesterol-lowering agents; however, many studies have
shown that they can be beneficial in as early as 6 months, as seen in the 4S trial [40].
2. Pharmacological therapies
2.1. Statins
Statins have been shown to be beneficial in hypercholesterolemia for both primary and
secondary prevention of CV events (see Figure 1) [41]. Their main mechanism of action
involves competitive inhibition of an enzyme, 3-Hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, a rate-limiting step in cholesterol synthesis (see Figure 2) [42, 43]. This
prevents substrate from binding to the enzymatic active site resulting in a decrease in intra-
hepatic cholesterol synthesis [44]. The decrease in intrahepatic cholesterol leads to an increase
in LDL receptors, and consequently an increase in LDL reuptake [45]. Other mechanisms
described include alteration of hepatic Apolipoprotein B (Apo-B) secretion leading to a
reduction in very low-density lipoprotein (VLDL) through decreased secretion and increased
clearance. This consequently also contributes to the reduction in plasma TG [46]. Statins’ effect
on HDL has been attributed to their impact on hepatic microRNA33 (miR33) and consequent
macrophage ATP-binding cassette transporter (ABCA)1-mediated efflux [47]. These additional
mechanisms are thought to translate into clinical benefit through varied pathways including
reversal of endothelial dysfunction, atheroma stabilization, and decreased thrombogenicity
[48].
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Figure 1. LDL, statins, and cardiovascular events. Reduction in cardiovascular event rates by lower low-density lipo-
protein using statins in secondary prevention trials. Abbreviations: 4S, Scandinavian Simvastatin Survival Study; CARE,
Cholesterol and Recurrent Events Trial; HPS, Heart Protection Study; LIPID, Long-term Intervention with Pravastatin
in Ischemic Disease.
Figure 2. Mechanisms of HMG-CoA reductase inhibitors. Statins inhibit hepatic HMG-CoA reductase resulting in de-
creased downstream cholesterol production.
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Statins are considered the most potent agents for lowering LDL cholesterol, and do so up to
63% [49]. They do have a predominant effect on small LDL particles leading to a shift in the
LDL subfractions toward less atherogenic LDL [50]. Rosuvastatin has been shown to increase
HDL by about 10%, appearing to be the most effective statins on HDL modification [51].
Regarding lowering TG, atorvastatin and rosuvastatin appear to be the most potent of the
statins, with a dose-dependent decrease in TG of up to 33% [51].
Statins as a drug category demonstrate varying cholesterol-lowering potencies (see Table 2)
[51–53]. Low-potency statins include simvastatin, lovastatin, pravastatin, and fluvastatin [51].
High-potency statins include atorvastatin and rosuvastatin [51]. Statins combined with a
cholesterol absorption inhibitor (such as ezetimibe) or bile acid sequestrant show an additive
cholesterol-lowering effect [54, 55].
Statin TC (%) LDL (%) HDL (%) TG (%) Dose range (mg)
Atorvastatin ↓ 27–39 ↓ 37–51 ↑ 2–6 ↓ 20–28 10–80
Rosuvastatin ↓ 33–40 ↓ 46–55 ↑ 8–10 ↓ 20–26 10–40
Simvastatin ↓ 20–28 ↓ 28–39 ↑ 5–6 ↓ 12–15 10–40
Pravastatin ↓ 15–22 ↓ 20–30 ↑ 3–6 ↓ 8–13 10–40
Fluvastatin ↓ 13–19 ↓ 17–23 ↑ 1–3 ↓ 5–13 20–80
Pitavastatin ↓ 22–31 ↓ 31–44 ↑ 1–4 ↓ 13–22 1–4
Abbreviations: NNT, number needed to treat; WOSCOPS, West of Scotland Coronary Prevention Study; AFCAPS/
TEXCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT, Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial; CARDS, Collaborative Atorvastatin Diabetes Study; MEGA,
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; JUPITER, Justification for
the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; 4S, Scandinavian Simvastatin Survival
Study; CARE, Cholesterol and Recurrent Events trial; LIPID, Long-Term Intervention with Pravastatin in Ischemic
Disease study;. HPS, Heart Protection Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk;
PROVE-IT, Pravastatin or Atorvastatin Evaluation and Infection Therapy; TNT, Treating to New Targets; IDEAL,
Incremental Decrease in End Points through Aggressive Lipid Lowering.
Table 2. Potencies of different statins.
Numerous clinical trials have shown a trend toward improved CV outcomes, but not all have
demonstrated statistical significance [56]. Statins have been shown to be effective in primary
prevention of CHD (see Table 3) 21, 25–28, 32, 41, 57–63]. This was demonstrated in the Heart
Protection Study [25], CARDS trial [26], and MEGA trial [27], where statins led to a significant
reduction in MACE. Statins have also been shown to be effective in the secondary prevention
of CHD as well (see Table 3). This benefit was evident in the Scandinavian Simvastatin Survival
study (4S) [28], Lipid trial [29], and MIRACLE [30], where statin use resulted in a significant
reduction in MACE. In a meta-analysis, which included 17,617 patients randomized to statins
from the Cholesterol and Recurrent Events (CARE), Long-term Intervention with Pravastatin
in Ischemic Disease (LIPID), and 4S trials, there was a significant reduction in MACE and all-
cause mortality, but no effect on noncardiovascular mortality [31]. In addition, high-dose statin
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therapy was shown to have a significant reduction in MACE when compared to lower-dose
therapy, as seen in the Treating to New Target (TNT) trial [41] and PROVE IT-TIMI 22 trial [32].
Study Year Patients Statin and
daily dose
Mean
baseline
LDL (mg/
dL) 
Mean LDL 
reduction 
(%)
Reduction in
coronary events
(%)
NNT
Primary prevention
WOSCOPS 1995 6595 Pravastatin 40 mg 192 26 31 (P < 0.001) 42
AFCAPS/
TEXCAPS
1998 6605 Lovastatin 20–40 mg 150 25 37 (P < 0.001) 24
ALLHAT-LLT 2002 10,355 Pravastatin 40 mg 146 28 No significant reduction
CARDS 2004 2838 Atorvastatin 10 mg 118 40 36 (P = 0.001) 32
MEGA 2006 7832 Pravastatin 10–20 mg 156 18 33 (P = 0.01) 119
JUPITER 2008 17,802 Rosuvastatin 20 mg 108 50 44 (P <0.001) 25
Secondary prevention
4S 1994 4444 Simvastatin 20–40 mg 188 35 34 (P < 0.0001) 15
CARE 1998 4159 Pravastatin 40 mg 139 32 24 (P = 0.003) 33
LIPID 2002 9014 Pravastatin 40 mg 150 25 24 (P < 0.0001) 33
HPS 2002 20,536 Simvastatin 40 mg 3.4 1 24 (P <0.001) 20
PROSPER 2002 5804 Pravastatin 40 mg 147 34 14(P = 0.014) 47
PROVE-IT 2004 4162 Atorvastatin 80 mg versus
Pravastatin 40 mg
106 41 16 (P = 0.005) 25
TNT 2005 10,003 Atorvastatin 80 mg versus
Atorvastatin 10 mg
97 21 22 (P <0.001) 46
IDEAL 2005 8888 Atorvastatin 80 mg versus
Simvastatin 20 mg
121 34 No significant reduction
Table 3. Primary and secondary prevention statin trials.
The most important side effects associated with statins are hepatic injury and myopathy [64,
65]. The risk of liver injury with the use of statins appears to be dose dependent and is most
likely to occur in the first 3 months. This risk was demonstrated in a meta-analysis of 35
randomized trials that showed an excess risk of 4.2 cases per 1000 patients associated with
statin use [66]. Multiple mechanisms of liver injury have been demonstrated with statins
including hepatocellular and cholestatic [67]. Among the different statins, the risk of liver
injury appears to be similar, except with fluvastatin that has a higher risk [68]. Numerous
studies have found no significant difference in elevated aminotransferases when statins were
compared to placebo [25, 28, 57]. It was for this reason that the Food and Drug Administration
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(FDA) revised the recommendation for liver function testing with regard to statin therapy in
2012 [69]. In the setting of rising aminotransferases three times the upper limit of normal, it is
recommended to lower the statin dose or change medication.
Statin muscle injury remains the most concerning side effect, despite severe myopathy
occurring in only 0.1–0.5% of patients [70, 71]. The degree of injury ranges from myalgia,
myopathy, myositis, myonecrosis, to rhabdomyolysis [65]. Rhabdomyolysis, the most severe
of the statin myopathy spectrum, was largely seen when statins were used with gemfibrozil
or cyclosporine [72, 73]. This is thought to be related to the decrease in mevalonic acid
associated with HMG-CoA reductase inhibition. Other mechanisms attributed to muscle injury
include statins’ effects on coenzyme Q10, also called ubiquinone, which is involved in muscle
energy production [74]. Different statins possess varying risk to cause muscle injury, with
fluvastatin exhibiting the lowest risk and simvastatin exhibiting a higher risk of muscle injury,
especially at 80 mg/day dose, as shown in the SEARCH trial that was the basis of the FDA
restriction of this dose of simvastatin [64, 70, 75]. The major predisposing factor for statin-
induced myopathy injury includes hypothyroidism, obstructive liver disease, and renal
failure; these contribute to both hypercholesterolemia and myopathy. Thus, it is important to
test for thyroid-stimulating hormone (TSH) levels prior to starting statins [76].
Other notable side effects include proteinuria that has been reported to the Food and Drug
Administration with rosuvastatin and simvastatin, but no increased risk of renal failure has
been described [77–79]. In addition, there have been several meta-analyses of randomized trials
that found a small, yet increased risk of diabetes with high-dose statin therapy when compared
to lower-dose statin therapies, possibly related directly to its inhibition of HMG-CoA reduc-
tase [80]. However, given that statins have been shown to reduce CV events in diabetics, these
studies have suggested that the beneficial effects of statins on CV events outweigh this risk [80,
81].
Despite physicians in practice witnessing the discontinuation of statins due to “intolerance,”
randomized control trials have failed to validate this finding. The difference between clinical
practice and trials may relate to selection bias observed in clinical trials that limit their external
validity [66, 82]. Intolerance is largely seen on the basis of muscle pain, leading to discontin-
uation of therapy. Another cause of intolerance is a rise in aminotransferases, which usually
requires statins dose reduction, switch to another statin, or using an alternate drug. In patients,
who are unable to tolerate statins, ezetimibe, fenofibrate, cholestyramine, and niacin have been
recommended for those with known coronary heart disease (CHD) or at high-risk CV events
(10-year risk >20%) [33]. Another option is the recently FDA-approved proprotein convertase
subtilisin kexin type 9 (PCSK9) inhibitors.
2.2. PCSK9 inhibitors
PCSK9 is a serine protease that is mainly secreted by the liver in an inactive form, before
undergoing catalytic changes in the endoplasmic reticulum. The mature PCSK9 is then
released into the plasma where it has only one substrate, LDL receptors. Once in circulation,
it regulates the LDL receptor recycling in the liver, intestines, pancreas, lungs, kidneys, and
adipose tissue [83, 84]. PCSK9 binding to LDL receptors causes it to be internalized into
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endosomal or lysosomal compartments, where they are destroyed. This leads to a decrease in
LDL receptors on the surface of the cell. It has therefore been shown that serum PCSK9 levels
are inversely proportional to the number of LDL receptors (see Figure 3) [85, 86]. Blood levels
of PCSK9 are influenced by the diurnal trend in secretion (peak levels at 4 am), gender (higher
in females), and fasting states (lower levels) [87, 88]. A mutation in PCSK9 was first described
in French families in 2003. It is the third gene implicated in the autosomal dominant familial
hypercholesterolemia (FH); the other two genes encode LDL receptor and Apo-B, a component
of the LDL particle [89]. It is usually a gain-of-function mutation in PCSK9 that results in a low
level of LDL receptors leading to a high level of LDL and consequently increased risk of
premature CV disease [90, 91]. On the other hand, loss-of-function PCSK9 mutations result in
high level of LDL receptors, and a decrease in LDL and significant reduction in CV events. Of
note, the reduction of CV events observed with PCSK9 mutation is higher than that associated
with statins. This difference is attributed to the persistently low LDL levels caused by the
underlying genetic predisposition. This was demonstrated in the ARIC study, Copenhagen
Heart Study, and the Zimbabwe population study [92–94].
Figure 3. Mechanisms of PCSK9 inhibitors. Secreted PCSK9 binds to LDL receptors on the cell surface and forms an
endosome that undergoes lysosomal degradation. In the presence of PCSK9 inhibitors, the interaction between PCSK9
and LDL receptors is disrupted, resulting in the recycling of LDL receptors and increased hepatic uptake of LDL from
the bloodstream. Abbreviations: LDL, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin
9.
Statins have been described to increase the concentration of PCSK9 inhibitors by 14–47% in a
dose- and time-dependent fashion. This is via a decrease in endogenous cholesterol synthesis
caused by statin inhibition of HMG-CoA reductase with consequent up-regulation in LDL
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receptors. It has therefore been demonstrated that a PCSK9 mutation increases the response
to statins [95–98]. Neutralizing antibodies to PCSK9 were first described in 2009, and in
subsequent studies it was shown to decrease LDL levels by 30% in animal models [99].
Although statins are the most effective cholesterol-lowering agents for preventing CV events,
there is a need for additional therapies in those patients who are (1) unable to take statins or
(2) already on maximal statin doses with residual CV risk. The National Lipid Association in
the US estimates that about 12% of patients discontinue statin therapy, of whom 62% experi-
enced adverse effects [100]. These data signal the need for alternative effective agents, such as
PCSK9 inhibitors, to be used with or instead of statins. As monotherapy, PCSK9 inhibitors
lower LDL by up to approximately 66% [101]. In conjunction with statins, PCSK9 inhibitors
reduce LDL by an additional 60% beyond statins [102]. Examples of monoclonal antibody
PCSK9 inhibitors available in the market include evolocumab and alirocumab. Phase I, II, and
III clinical trials have shown an additional decrease in LDL levels with the use of PCSK-9
inhibitors (monoclonal antibodies) in combination with statin therapy, as well as a significant
decrease in CV events including mortality (hazard ratio (HR): 0.47–0.52) [2, 3]. Other PCSK9
inhibitors include the small interfering RNA (siRNA) molecules that block the synthesis of
PCSK9 inhibitors and have been shown to decrease LDL by 40% in a phase I clinical trial when
used at the highest dose compared to placebo [103].
Regarding their side effects, there were no significant differences in the incidence of adverse
drug events between PCSK9 inhibitors (alirocumab, evolocumab) and placebo in the latest
phase III trials, except for neurocognitive events, myalgia, injection site reactions, and oph-
thalmologic events [2, 3]. A major concern with PCSK9 inhibitors revolves around their cost
and the very low LDL levels achieved (as low as 18 mg/dL compared to 44 mg/dL with
rosuvastatin in the JUPITER study). Potential short- and long-term consequences of very low
LDL levels include neurocognitive impairment, hemorrhagic stroke, hemolytic anemia,
vitamin, and hormonal deficiencies [21, 104].
2.3. Ezetimibe
Ezetimibe inhibits the intestinal absorption of dietary and biliary cholesterol without affecting
the absorption of fat-soluble vitamins or TG [105]. This possibly occurs by the inhibition of
Niemann-Pick C1-like 1 (NPC1L1) protein function that is expressed in the intestines and liver
[106]. The benefits of ezetimibe were demonstrated in the IMPROVE-IT trial where the addition
of ezetimibe to statin therapy led to a decrease in CV events, excluding all-cause and CV
mortality [54]. Ezetimibe is helpful in avoiding high doses of statin and the associated dose-
dependent statin side effects, especially in patients who do not meet cholesterol targets. It has
been well tolerated with the incidence of myopathy and serum transaminase elevations being
similar when compared to placebo [54].
2.4. Bile acid sequestrants
Bile acid sequestrants, such as cholestyramine, colesevelam, and colestipol, lower cholesterol
by binding to bile acids in the intestine preventing them from being reabsorbed [107]. The
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consequent decrease in intrahepatic cholesterol leads to an increase in LDL receptors that bind
LDL from plasma with consequent small increase in HDL via increased intestinal synthesis of
HDL [108]. They are relatively potent and exhibit a dose-dependent response achieving 10–
25% reduction in LDL, exhibiting a synergistic effect when used with statins or niacin [55, 109,
110].
Major side effects have limited its overall use. Those described include abdominal discomfort
with nausea, bloating, cramping, and rise in aminotransferases. Of the bile acid sequestrants,
colesevelam is the better-tolerated drug. They also interact with common CV medications
(warfarin and digoxin) by binding and inhibiting their absorption. This can be avoided by
administering the other medications 1 h before or 4 h after ingestion of bile acid sequestrants
[107].
2.5. Fibrates
Fibrates include gemfibrozil and fenofibrate [111]. The mechanism of action of fibrates is via
activation of transcription factor, peroxisome proliferator-activated receptors (PPARs). It
decreases TG via reduction in hepatic VLDL secretion, and stimulation of lipoprotein lipase
that consequently leads to increased clearance of TG-rich lipoproteins. It also raises HDL by
direct stimulation of HDL Apolipoprotein A-I/A-II synthesis and increased transfer of Apo A-
I from HDL to VLDL [112].
This class of drugs lowers serum TG by 35–50%, and have also been shown to increase HDL
by 5–20% directly proportional to the degree of hypertriglyceridemia [113–115]. Fibrates have
not demonstrated any significant effect on cardiovascular outcomes, as seen in the FIELD trial
[115], except in those with high TG (>200 mg/dL) or low HDL (<40 mg/dL) and metabolic
syndrome, as was seen in the BIP trial [116].
The main side effect associated with fibrates is muscle injury. Muscle injury is often seen in
patients who are already on a statin, and is thought to be mediated by fibrate-related inhibition
of CYP3A4 with consequent decrease in statin metabolism [117]. Fibrates have also been shown
to raise serum creatinine levels, but it remains unknown if there is direct parenchymal or
tubular renal injury. Nevertheless, elevated creatinine has been found to be reversible on
discontinuation of the medication, as was demonstrated in the FIELD trial [118]. Another
noteworthy side effect is pancreatitis, which has been seen in patients with normal TG.
However, the absolute risk remains low (number needed to harm over 5 years = 935) [119].
2.6. Nicotinic acid (niacin)
Nicotinic acid acts by inhibiting the hepatic production of VLDL and consequently decreasing
LDL. It also increases HDL by reducing lipid transfer from HDL to VLDL, thus delaying HDL
clearance [120]. This class of drugs has positive effects on HDL that occurs at relatively low
dosages (1–1.5 g/day result in about 33% increase in HDL). Higher nicotinic acid doses are
needed to lower LDL (3 g/day results in about 23% LDL decrease) [121, 122]. This class of drugs
is also associated with a significant reduction of MACE in the HATS trial and ARBITER 6-
HALTS trial when niacin was added to statin therapy [123, 124]. Contrary to these studies, the
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AIM-HIGH, ARBITER-2, and HPS2-THRIVE trials found no significant benefit of adding
niacin to statin therapy [125–127].
Unfortunately, its use is limited by poor tolerability. The most common side effect is flushing,
which occurs in the majority (up to 80%) of patients at standard recommended doses. Other
notable side effects include paresthesia, pruritis, and nausea, each of which occurs in 20% of
patients at standard doses [120].
3. Lifestyle modification
All patients with an elevated LDL should be advised to attempt and undergo for therapeutic
lifestyle changes. Therapeutic lifestyle changes involve weight loss (even in those who are only
slightly overweight), exercise, and improvement in diet. Numerous studies have investigated
and demonstrated the benefits of lifestyle modification. In the United Kingdom Lipid Clinics
Program study, 2508 subjects who underwent diet modification experienced a 5–7% reduction
in serum total and LDL cholesterol [128]. In the Lifestyle Heart Trial, 53 patients were random-
ized to either control diet (National Cholesterol Education Program-NCEP step 2 diet) or
vegetarian therapy with exercise and relaxation therapy (intervention group). After 5 years of
follow-up, the intervention group demonstrated a decrease in CV events (0.89 vs 2.25 events
per patient) [129]. In the Lyon Diet Heart Study, 605 patients were randomized after a first
myocardial infarction to either a Mediterranean diet or a control diet. After 4 years of follow-
up, the Mediterranean diet group demonstrated lower rates of death and myocardial infarc-
tion [130].
4. Other potential therapy options
Statins are the preferred therapy for most patients with dyslipidemia, especially those with
elevated total cholesterol and LDL cholesterol. However, in patients on maximal tolerated
statin dose with a persistently elevated LDL, other therapies may be considered. These include
niacin, bile acid sequestrants, and ezetimibe. Not uncommonly, these additional agents may
not be sufficient to “normalize” abnormal cholesterol profiles, especially in patients with severe
hypercholesterolemia and familial cholesterol diseases. Therapeutic options in this group of
patients, who remain “at risk” for CV events, include LDL apheresis, lomitapide, surgical
options, and gene therapy. Preferably, this cohort of patients should be managed by a specialist.
4.1. LDL apheresis
LDL apheresis is a procedure that involves extracorporeal removal of circulating Apo B-
containing lipoprotein (e.g., LDL, VLDL, and lipoprotein-a). Regimens include weekly or
biweekly depending on the rate LDL returns to baseline after therapy [131].
The National Lipid Associated Expert Panel on familial hypercholesterolemia recommended
LDL apheresis in those with FH if LDL targets are not achieved with maximal tolerated medical
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therapy. These targets include LDL of ≥300 mg/dL in those with functional homozygous or
heterozygous FH, LDL of ≥200 mg/dL in those with functional heterozygous FH, and ≥2 risk
factors or high lipoprotein-a (≥50 mg/dL), or LDL of ≥160 mg/dL in those established CAD, CV
disease, or diabetes [132]. In the absence of statin therapy, LDL apheresis lowers LDL by 50–
75% acutely, by 30% after 6 months, and 38% after 18 months [133]. There are numerous studies
showing benefit in outcomes such as myocardial infarction and reduction in arterial inflam-
mation, but none have shown a survival benefit [134, 135]. Limitations to using LDL apheresis
include patient burden, problems related to venous access, frequent long visits, and high costs
[136].
4.2. Lomitapide
Lomitapide is a microsomal TG transfer protein inhibitor which inhibits the transfer of TG to
Apo-B for the production of VLDL in the liver. However, lomitapide is metabolized by CYP3A4
and is also an inhibitor of CYP 3A4 and P-glycoprotein leading to numerous drug interactions.
It was FDA approved in 2012 for use in patients with homozygous FH. It is used in addition
to standard therapy, as well as other therapies such as LDL apheresis or liver transplantation.
It has been shown to significantly decrease LDL (up to 50%) in a phase 3, open-label, non-
randomized, dose-escalating study [137].
4.3. Mipomersen
Mipomersen is an injected antisense oligonucleotide that inhibits the production of Apo-B.
Mipomersen binds to the Apo-B mRNA, affects Apo-B production, and consequently reduces
the levels of LDL, VLDL, and intermediate dense lipoprotein. It has been approved by FDA in
2013 for use in homozygous FH patients; however, it is not approved in Europe. It has been
shown that mipomersen can significantly decrease LDL in those patients with homozygous
FH (up to 25%) [138]. Similar findings were found in studies involving other populations,
including those with heterozygous FH and have CAD, statin intolerant, and at high risk of CV
disease, and in those without FH who have or are at high risk of CVD [139–143].
4.4. Cholesteryl ester transfer protein inhibitors
Cholesteryl ester transfer protein (CETP) inhibitors, such as anacetrapib, have shown to
significantly increase in HDL and lower LDL; however, there are no studies showing clinical
benefit. In fact, in the REALIZE trial, despite a significant reduction in LDL in the intervention
group compared to placebo, there was a significant increase in CV events, hence limiting its
clinical use [144].
4.5. Anti-resistin antibodies
Anti-resistin antibodies inhibit resistin function, an adipokine (protein derived from adipose
tissue) that is increased in obese individuals and positively correlated with atherosclerosis. In
in vitro studies, resistin can decrease LDL receptor expression and increase PCSK9 expression.
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By using anti-resistin antibodies, studies have shown an increase in LDL receptors in obese
individuals [145].
4.6. Small molecule regulator of lipid metabolism
ETC-1002 is a small molecule regulator of carbohydrate and lipid metabolism. In a study of
177 subjects with LDL between 130 and 220 mg/dL not on statin therapy, patients were
randomized to ETC-1002 (one of three different doses) or placebo. After 12 weeks of follow-
up, treated subjects at the highest dose demonstrated a 27% decrease in LDL. There were no
changes in TG or HDL. ETC-1002 also demonstrated a limited side effect profile [146, 147].
4.7. Recombinant Apo-A-I milano
Apo-A-I milano is a variant of the Apolipoprotein A-I (Apo-A-I). This variant leads to rapid
mobilization of cholesterol with rapid regression of atherosclerosis. Subjects with Apo-A-I
Milano have very low levels of HDL (10–30 mg/dL), longer survival, and reduced atheroscle-
rosis compared to what is expected for their HDL levels [148]. Infusion of recombinant Apo-
A-I milano (ETC-216) in an RCT was shown to lead to a significant regression of coronary
atherosclerosis [149].
4.8. Lipoprotein-associated phospholipase A2
Lipoprotein-associated phospholipase A2 is also known as platelet-activating factor acetylhy-
drolase. It is a protein with pro-inflammatory properties that co-travels with circulating LDL
particles and is found abundantly in atherosclerotic plaques [150]. Lipoprotein-associated
phospholipase A2 has been shown in a meta-analysis to significantly increase CHD and is an
independent predictor of CHD and ischemic stroke [151]. However, in a large phase III
randomized control trial (STABILITY trial), the lipoprotein-associated phospholipase A2
inhibitor, darapladib, failed to show any CV benefit [152].
5. Conclusion
Over the last several years, the role of cholesterol-lowering agents in reducing cardiovascular
disease and mortality has been further established. Statin therapy remains the cornerstone of
lipid-lowering therapy; however, in patients already on maximal dose of statins or intolerant
to statins with residual CV risk, other options are also available. As evidenced by the recent
bench to bedside development of a new drug class (PCSK9), the emergence of drugs to
specifically target a population, in this case, familial hypercholesterolemia, the national call
for precision medicine is on the horizon. By continuing to scientifically probe biologic mech-
anisms in preclinical models related to cholesterol perturbation, drug development and
translation to human clinical studies marks a bright and promising future.
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